Document Detail

Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients.
MedLine Citation:
PMID:  15331796     Owner:  NLM     Status:  MEDLINE    
BACKGROUND AND PURPOSE: Bleeding risks from combined antiplatelet-warfarin therapy have not been well-described in clinical practice. We examined antiplatelet therapy among warfarin users and the impact on major bleeding rates. METHODS: Retrospective cohort analysis of persons discharged on warfarin after an atrial fibrillation admission using data from Medicare's National Stroke Project. Data included Medicare claims, enrollment information, and medical record abstracted data. Logistic regression and Cox proportional hazards models were used to predict concurrent antiplatelet use and hospitalization with a major acute bleed within 90 days after discharge from the index AF admission. RESULTS: 10,093 warfarin patients met inclusion criteria with a mean age of 77 years; 19.4% received antiplatelet therapy. Antiplatelet use was less common among women, older persons, and persons with cancer, terminal diagnoses, dementia, and bleeding history. Persons with coronary disease were more likely to receive an antiplatelet agent. Antiplatelets increased major bleeding rates from 1.3% to 1.9% (P=0.052). In the multivariate analysis, factors associated with bleeding events included age (OR, 1.03; 95% CI, 1.002 to 1.05), anemia (OR, 2.52; 95% CI, 1.64 to 3.88), a history of bleeding (OR, 2.40; 95% CI, 1.71 to 3.38), and concurrent antiplatelet therapy (OR, 1.53; 95% CI, 1.05 to 2.22). CONCLUSIONS: Although concerns about increased bleeding risk with combined warfarin-antiplatelet therapy are not unfounded, the risk of bleeding is moderately increased. The decision to use concurrent antiplatelet therapy appears to be tempered by cardiac and bleeding risk factors.
Theresa I Shireman; Patricia A Howard; Timothy F Kresowik; Edward F Ellerbeck
Related Documents :
17443526 - Treatment of vaginal bleeding irregularities induced by progestin only contraceptives.
20966706 - The oncogenic potential of endometrial polyps: a systematic review and meta-analysis.
10359406 - Low-potency oestrogen and risk of endometrial cancer: a case-control study.
16414216 - Are endometrial polyps from pre-menopausal women similar to post-menopausal women? an i...
24981006 - Experiences of forced sex among female patrons of alcohol-serving venues in a south afr...
11581096 - Low-to-moderate alcohol consumption and breast cancer risk by age 50 years among women ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2004-08-26
Journal Detail:
Title:  Stroke; a journal of cerebral circulation     Volume:  35     ISSN:  1524-4628     ISO Abbreviation:  Stroke     Publication Date:  2004 Oct 
Date Detail:
Created Date:  2004-09-24     Completed Date:  2005-03-22     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0235266     Medline TA:  Stroke     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2362-7     Citation Subset:  IM    
Pharmacy Practice Department, University of Kansas School of Pharmacy, 1251 Wescoe Hall Drive, Lawrence, KS 66045, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticoagulants / adverse effects,  therapeutic use*
Atrial Fibrillation / complications,  drug therapy*
Drug Therapy, Combination
Hemorrhage / epidemiology*
Platelet Aggregation Inhibitors / adverse effects,  therapeutic use*
Proportional Hazards Models
Retrospective Studies
Stroke / etiology,  prevention & control*
Warfarin / adverse effects,  therapeutic use*
Reg. No./Substance:
0/Anticoagulants; 0/Platelet Aggregation Inhibitors; 81-81-2/Warfarin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Polymorphisms in genes involved in inflammatory and angiogenic pathways and the risk of hemorrhagic ...
Next Document:  Hourly blood pressure monitoring after intravenous tissue plasminogen activator for ischemic stroke:...